Samsung Provides One-Stop Foundry Design Environment with the Launch of ‘SAFE™ Cloud Design Platform’
18.6.2020 10:00:00 EEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced the launch of ‘Samsung Advanced Foundry Ecosystem (SAFE™) Cloud Design Platform (CDP)’ for fabless customers, in collaboration with Rescale, a leader in high performance computing (HPC) applications in the cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005278/en/
Samsung Advanced Foundry Ecosystem (Graphic: Buisness Wire)
The key highlight feature of Samsung foundry’s first SAFE™ Cloud Design Platform is that it provides a virtual environment to design chips in the cloud. By accessing this platform through the cloud, customers can immediately start designing at anytime and anywhere.
To maximize customers’ design convenience, SAFE™ CDP supports a very secure design condition that has verified with cloud companies. In addition, customers can utilize various Electronic Design Automation (EDA) tools offered by multiple vendors such as Ansys, Cadence, Mentor, a Siemens business and Synopsys.
Gaonchips, one of Samsung Foundry’s Design Solution Partners, has already tested the SAFE™ CDP on its14nm automotive project using Cadence’s Innovus Implementation System and has successfully reduced its design run-time by 30 percent compared to current on-premise execution
“We expect that our innovative design platform co-developed in partnership with Rescale will play a crucial role for the fabless industry as it evolves into efficient cloud-based design environment,” said Jae-hong Park, executive vice president of Foundry Design Platform Development at Samsung Electronics. “We remain committed to our efforts to bolster the SAFE™ ecosystem and will continue to collaborate with our SAFE™ partners on developing innovative programs that will help deliver ease of use and greater design efficiency for customers”
As designs move to advanced nodes and as transistor scaling occurs at each node, chip designs become more complex and computing power required for these designs have increased significantly, resulting in greater overhead time and cost to customers.
By adopting CDP, customers can reduce the burden of building their own server infrastructure, while flexibly utilizing additional computing power required for chip design and verification. Furthermore, they can take full advantage of Samsung’s diverse foundry ecosystem which includes EDA, intellectual property (IP), cloud, and design services offered by reputable partners.
“We are excited to be a partner of Samsung Foundry SAFE™ ecosystem,” said Joris Poort, founder and CEO of Rescale. “We share a common vision of a global design cloud platform that efficiently supports a broad ecosystem of technologies and services for EDA customers worldwide.”
To actively respond to the latest technology trends and lower the design barrier for developing competitive SoCs, Samsung launched the SAFETM program in early 2018 and held the first SAFETM Forum in the United States last year. More information on SAFETM can be found here .
About Samsung Electronics Co., Ltd.
Samsung Electronics inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
About Rescale
Rescale is the leader in enterprise big compute in the cloud. Rescale’s ScaleX® multi-cloud platform, built on the most powerful high-performance computing infrastructure, seamlessly matches software applications with the best architecture in the cloud to run complex data processing and simulations. Rescale partners with the largest cloud service providers such as Amazon Web Service, Microsoft Azure, Google Cloud Platform, IBM, and Oracle Cloud Infrastructure, providing services enterprise in automotive, aerospace, defense, and semiconductor industry. For more information on Rescale, visit www.rescale.com.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005278/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)6196-66-3300
Email: ujeong.j@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom